Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Sanofi expands rare immunology portfolio with Blueprint buyout
Moderna's next-gen COVID shot gets FDA backing with some limitations
BioNTech flips its cancer bispecific to BMS for a big profit
*please scroll down for all the latest news *
Make it like cafepharma, but for different industries. Learn more about CompanyUnderground
Check open job listings in your area
Click here to stay updated on CP happenings
learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud
Sanofi expands rare immunology portfolio with Blueprint buyout
Moderna's next-gen COVID shot gets FDA backing with some limitations
BioNTech flips its cancer bispecific to BMS for a big profit
*please scroll down for all the latest news *
Make it like cafepharma, but for different industries. Learn more about CompanyUnderground
Check open job listings in your area
Click here to stay updated on CP happenings
learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud